Originally published by our sister publication Anesthesiology News
The largest trial of tranexamic acid (TXA) ever performed has shed much-needed light on the drug’s cardiovascular effects in patients undergoing major noncardiac surgery, and the results are somewhat surprising.
The POISE-3 (PeriOperative ISchemic Evaluation-3) trial concluded that patients treated with TXA not only had significantly fewer serious bleeding events than those treated with placebo, but also did not suffer more